1. Home
  2. MIRM vs WRBY Comparison

MIRM vs WRBY Comparison

Compare MIRM & WRBY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MIRM
  • WRBY
  • Stock Information
  • Founded
  • MIRM 2018
  • WRBY 2010
  • Country
  • MIRM United States
  • WRBY United States
  • Employees
  • MIRM N/A
  • WRBY N/A
  • Industry
  • MIRM Biotechnology: Pharmaceutical Preparations
  • WRBY Ophthalmic Goods
  • Sector
  • MIRM Health Care
  • WRBY Health Care
  • Exchange
  • MIRM Nasdaq
  • WRBY Nasdaq
  • Market Cap
  • MIRM 2.5B
  • WRBY 2.7B
  • IPO Year
  • MIRM 2019
  • WRBY 2021
  • Fundamental
  • Price
  • MIRM $51.12
  • WRBY $23.67
  • Analyst Decision
  • MIRM Strong Buy
  • WRBY Buy
  • Analyst Count
  • MIRM 9
  • WRBY 16
  • Target Price
  • MIRM $66.22
  • WRBY $23.20
  • AVG Volume (30 Days)
  • MIRM 351.2K
  • WRBY 1.5M
  • Earning Date
  • MIRM 08-11-2025
  • WRBY 08-07-2025
  • Dividend Yield
  • MIRM N/A
  • WRBY N/A
  • EPS Growth
  • MIRM N/A
  • WRBY N/A
  • EPS
  • MIRM N/A
  • WRBY N/A
  • Revenue
  • MIRM $379,251,000.00
  • WRBY $795,094,000.00
  • Revenue This Year
  • MIRM $36.76
  • WRBY $16.06
  • Revenue Next Year
  • MIRM $17.48
  • WRBY $14.17
  • P/E Ratio
  • MIRM N/A
  • WRBY N/A
  • Revenue Growth
  • MIRM 69.31
  • WRBY 13.94
  • 52 Week Low
  • MIRM $36.20
  • WRBY $12.46
  • 52 Week High
  • MIRM $54.78
  • WRBY $28.68
  • Technical
  • Relative Strength Index (RSI)
  • MIRM 50.28
  • WRBY 59.03
  • Support Level
  • MIRM $50.92
  • WRBY $23.33
  • Resistance Level
  • MIRM $52.63
  • WRBY $24.60
  • Average True Range (ATR)
  • MIRM 1.49
  • WRBY 0.81
  • MACD
  • MIRM -0.35
  • WRBY -0.05
  • Stochastic Oscillator
  • MIRM 5.30
  • WRBY 58.52

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

About WRBY Warby Parker Inc.

Warby Parker Inc is a mission-driven, lifestyle brand that operates at the intersection of design, technology, healthcare, and social enterprise. The company predominantly derives revenue from the sales of eyewear products, optical services, and accessories. The firm sells products and services through its stores, website, and mobile apps. Revenue generated from eyewear products includes the sales of prescription and non-prescription optical glasses and sunglasses, contact lenses, eyewear accessories, and expedited shipping charges.

Share on Social Networks: